INPP4B suppresses HER2-induced mesenchymal transition in HER2+ breast cancer and enhances sensitivity to Lapatinib
- 7 June 2024
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 226, 116347
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Cibler HER2 dans le cancer colorectalBulletin du Cancer, 2023
- Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimensBreast Cancer Research and Treatment, 2021
- Copper Promotes Tumorigenesis by Activating the PDK1‐AKT Oncogenic Pathway in a Copper Transporter 1 Dependent MannerAdvanced Science, 2021
- Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆Annals of Oncology, 2020
- Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cellsInflammopharmacology, 2020
- Emerging Biological Principles of MetastasisCell, 2017
- INPP4B reverses docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancerBiochemical and Biophysical Research Communications, 2016
- INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cellsTumor Biology, 2014
- Epidermal growth factor-related peptides and their receptors in human malignanciesCritical Reviews in Oncology/Hematology, 1995
- Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancerHuman Pathology, 1992